Shamburg News · 8-K filed Nov 10, 2026, 8:02 AM EST
Coya Therapeutics Reports Third Quarter 2026 Results; ALSTARS Enrollment Completed
COYA · Coya Therapeutics, Inc.
- Earnings
- Other event
- Materiality: high
Coya Therapeutics reported a net loss of $10.6 million, or $0.45 per share, for the three months ended September 30, 2026, compared with a net loss of $2.1 million for the same period in 2025. Collaboration revenue was $0.2 million, down from $3.6 million a year earlier, while research and development expenses rose to $8.6 million. The company also said enrollment is complete in the Phase 2/3 ALSTARS trial of COYA 302 with 137 participants, and reported cash and cash equivalents of $35.8 million as of September 30, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-454473.
Written from the filing by Shamburg Markets. Figures are as reported by the company.